TME PHARMA NV (ALTME.PA) Stock Fundamental Analysis
Europe • Euronext Paris • EPA:ALTME • NL0015000YE1
0.072 EUR
-0.01 (-15.29%)
Last: Jan 30, 2026, 07:00 PM
Taking everything into account, ALTME scores 0 out of 10 in our fundamental rating. ALTME was compared to 85 industry peers in the Biotechnology industry. ALTME may be in some trouble as it scores bad on both profitability and health. ALTME has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- ALTME had negative earnings in the past year.
- ALTME had a negative operating cash flow in the past year.
- In the past 5 years ALTME always reported negative net income.
- In the past 5 years ALTME always reported negative operating cash flow.
1.2 Ratios
- ALTME's Return On Assets of -199.56% is on the low side compared to the rest of the industry. ALTME is outperformed by 88.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -199.56% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-242.38%
ROA(5y)-194.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for ALTME so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ALTME has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for ALTME has been increased compared to 5 years ago.
- There is no outstanding debt for ALTME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -127.65, we must say that ALTME is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of ALTME (-127.65) is worse than 88.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -127.65 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- ALTME has a Current Ratio of 0.79. This is a bad value and indicates that ALTME is not financially healthy enough and could expect problems in meeting its short term obligations.
- ALTME's Current ratio of 0.79 is on the low side compared to the rest of the industry. ALTME is outperformed by 72.94% of its industry peers.
- ALTME has a Quick Ratio of 0.79. This is a bad value and indicates that ALTME is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 0.79, ALTME is doing worse than 70.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 86.56% over the past year.
EPS 1Y (TTM)86.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 53.46% on average over the next years. This is a very strong growth
- The Revenue is expected to decrease by -25.99% on average over the next years. This is quite bad
EPS Next Y89.47%
EPS Next 2Y21.4%
EPS Next 3Y53.46%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- ALTME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALTME. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ALTME's earnings are expected to grow with 53.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.4%
EPS Next 3Y53.46%
5. Dividend
5.1 Amount
- ALTME does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TME PHARMA NV / ALTME.PA FAQ
What is the ChartMill fundamental rating of TME PHARMA NV (ALTME.PA) stock?
ChartMill assigns a fundamental rating of 0 / 10 to ALTME.PA.
What is the valuation status for ALTME stock?
ChartMill assigns a valuation rating of 1 / 10 to TME PHARMA NV (ALTME.PA). This can be considered as Overvalued.
What is the profitability of ALTME stock?
TME PHARMA NV (ALTME.PA) has a profitability rating of 0 / 10.